Results 81 to 90 of about 134,499 (99)

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

open access: yesMolecular Cancer Therapeutics, 2011
International audienceGA101 is a novel glycoengineered Type II CD20 monoclonal antibody. When compared with rituximab, it mediates less complement-dependent cytotoxicity (CDC).
Christian Klein   +2 more
exaly   +2 more sources

Unexpected Cross-Reactivity of Anti-Cathepsin B Antibodies Leads to Uncertainties Regarding the Mechanism of Action of Anti-CD20 Monoclonal Antibody GA101

open access: yesLeukemia Research, 2017
International audienceGA101, also known as obinutuzumab or Gazyva (Gazyvaro), is a glycoengineered type II humanized antibody that targets the CD20 antigen expressed at the surface of B-cells.
Abdel Aouacheria   +2 more
exaly   +2 more sources

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

open access: yesJournal of Clinical Oncology, 2013
International audiencePurposeObinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models.
Gilles Salles   +2 more
exaly   +2 more sources

Epitope Characterization and Crystal Structure of GA101 Provide Insights Into the Molecular Basis for Type I/II Distinction of CD20 Antibodies [PDF]

open access: yesBlood, 2011
CD20 is a cell-surface marker of normal and malignant B cells. Rituximab, a monoclonal antibody targeting CD20, has improved the treatment of malignant lymphomas.
Christian Klein   +2 more
exaly   +2 more sources

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

open access: yesJournal of Clinical Oncology, 2015
Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma.
Andre H Goy   +2 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

The Journal of Immunology | Oxford Academic

Journal of Immunology, 2011
Martino Introna   +2 more
exaly  

Home - About - Disclaimer - Privacy